Overview

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Status:
Terminated

Trial end date:
2020-09-25

Target enrollment:

Participant gender:

Summary

This is a single-arm, open label, Phase II study evaluating the safety and efficacy of neoadjuvant Nivolumab and HF10 in resectable stage IIIB, IIIC, and IVM1a melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Collaborators:

Bristol-Myers Squibb
Takara Bio Inc.

Treatments:

Antibodies, Monoclonal
Nivolumab